Posted by Michael Wonder on 20 Dec 2022
Radicava (edaravone) oral suspension receives positive recommendation from INESSS for the treatment of patients with ALS
19 December 2022 - Mitsubishi Tanabe Pharma Canada is pleased to announce a positive recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for Radicava oral suspension, the oral formulation of Radicava IV (edaravone), for the treatment of patients with amyotrophic lateral sclerosis.
Full details on the recommendation by INESSS, including recommended criteria for reimbursement, are available on the INESSS website.
